Adamis Pharmaceuticals Receives a Complete Response Letter from the FDA Regarding Zimhi

SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) today announced that after the close of business and the U.S. markets on November 13th, it received a Complete Response Letter...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news